< Back

MARK PEARSON

In 1994 Mr. Pearson founded Catalyst Real Estate Group, a corporate real estate services firm specializing in the representation of biotechnology, pharmaceutical and technology companies. In 1998 Catalyst Real Estate Group merged with three other independent real estate firms to form CRESA Partners ("CRESA"). Serving as Co-Founder, Managing Partner and Board Member of CRESA, Mr. Pearson was instrumental in building CRESA into a 57-office national corporate real estate services firm. In 2015, Mr. Pearson sold his interest in CRESA to Savills, a $2.4 billion international real estate services firm with over 700 offices and 39,000 employees. Mr. Pearson continues his involvement in Savills as an Executive Managing Director.

Mr. Pearson is the Founder and Chief Executive Officer of Altamont Pharmaceutical Holdings, LLC., a healthcare investment firm focused on investing in and building life science companies as well as Co-Founder and Managing Partner of Annex Ventures, a venture capital firm. Mark is the Founder and Co-Chairman of Cessation Therapeutics, LLC., a preclinical-stage biopharmaceutical company based in La Jolla, California. Mr. Pearson serves on the Board of Trustees of the Scripps Research Institute, a world-renowned biomedical institute employing over 2,400 scientists and support staff. Scripps Research Institute has created 80+ spin-off biotech companies, 10 FDA approved drugs, and currently has 30 drugs in its pipeline. Mr. Pearson holds a Bachelor of Science degree in Economics from the University of San Francisco and a Masters degree in Management from Stanford University Graduate School of Business where he was a Sloan Fellow.